Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Ignacio Hanna-Jairala, Douglas A Drossman
Irritable bowel syndrome are responsive to treatments using central neuromodulators. Central neuromodulators work by enhancing the synaptic transmission of 5-hydroxytryptamine, noradrenalin and dopamine, achieving a slower regulation or desensitization of their postsynaptic receptors. Central neuromodulators act on receptors along the brain-gut axis, so they are useful in treating psychiatric comorbidities, modifying gut motility, improving central downregulation of visceral signals and enhancing neurogenesis in patients with IBS...
April 9, 2024: American Journal of Gastroenterology
#2
JOURNAL ARTICLE
Olafur S Palsson, Jan Tack, Douglas A Drossman, Boris Le Nevé, Laurent Quinquis, Rim Hassouna, Johannah Ruddy, Carolyn B Morris, Ami D Sperber, Shrikant I Bangdiwala, Magnus Simrén
BACKGROUND: The Rome Foundation Global Epidemiology Study (RFGES) found that 40.3% of adults in 26 internet-surveyed countries met Rome IV criteria for disorders of gut-brain interaction (DGBI). However, additional people not meeting DGBI criteria may also be burdened by frequent gastrointestinal symptoms. AIMS: To explore the prevalence and demographic distribution of sub-diagnostic gastrointestinal symptoms, and the hypothesised associated effects on quality of life (QoL), life functioning and healthcare needs...
February 4, 2024: Alimentary Pharmacology & Therapeutics
#3
JOURNAL ARTICLE
B Joseph Elmunzer, Olafur S Palsson, Nauzer Forbes, Ali Zakaria, Christian Davis, Andrew Canakis, Emad Qayed, Benjamin Bick, Swati Pawa, William M Tierney, Caroline G McLeod, Jason Taylor, Harsh Patel, Robin B Mendelsohn, Gokul Bala, Ian Sloan, Ambreen A Merchant, Zachary L Smith, Morgan A Sendzischew Shane, Olga C Aroniadis, Collins O Ordiah, Johannah M Ruddy, Magnus Simren, Jan Tack, Douglas Drossman
BACKGROUND & AIMS: Acute enteric infections are well known to result in long-term gastrointestinal (GI) disorders. Although COVID-19 is principally a respiratory illness, it demonstrates significant GI tropism, possibly predisposing to prolonged gut manifestations. We aimed to examine the long-term GI impact of hospitalization with COVID-19. METHODS: Nested within a large-scale observational cohort study of patients hospitalized with COVID-19 across North America, we performed a follow-up survey of 530 survivors 12-18 months later to assess for persistent GI symptoms and their severity, and for the development of disorders of gut-brain interaction (DGBIs)...
November 22, 2023: Clinical Gastroenterology and Hepatology
#4
JOURNAL ARTICLE
Briana M Nosal, Junichi R Sakaki, Manije Darooghegi Mofrad, Zachary Macdonald, Kyle J Mahoney, Staci N Thornton, Dave Patel, Joseph Drossman, Elaine Choung-Hee Lee, Ock K Chun
Recent cell and animal studies suggest the potential of blackcurrants (BCs; Ribes nigrum ) as a dietary agent that may reduce the risk of cardiovascular disease (CVD) by improving dyslipidemia, oxidative stress, and inflammation. This study aimed to examine the effects of BC anthocyanin (ACN) extract supplementation on biomarkers of CVD risk in healthy adult women in menopause transition. The effects of BC ACN supplementation on body composition, fasting blood lipids and biomarkers of inflammation and oxidative stress were evaluated using anthropometric measures and blood samples collected from a pilot randomized controlled clinical trial in peri- and early postmenopausal women...
October 19, 2023: Biomedicines
#5
JOURNAL ARTICLE
Darren M Brenner, Maura Corsetti, Douglas Drossman, Jan Tack, Arnold Wald
BACKGROUND & AIMS: Functional constipation is the most common of the disorders of gut-brain interaction, affecting approximately 12% of the world population. Although classically considered a chronic condition, many individuals experience shorter yet repetitive bouts of constipation representing a different clinical entity. There has been increased interest in this latter disorder, which has recently been classified as occasional constipation. This Rome Foundation working group document reflects the consensus of an international team of specialists who summarized currently available research to provide a working definition of and treatment algorithm for occasional constipation...
October 4, 2023: Clinical Gastroenterology and Hepatology
#6
JOURNAL ARTICLE
Inês A Trindade, Jóhann P Hreinsson, Chloé Melchior, Joost P Algera, Esther Colomier, Hans Törnblom, Douglas Drossman, Jan Tack, Olafur S Palsson, Shrikant I Bangdiwala, Ami D Sperber, Magnus Simrén
INTRODUCTION: This study focused on defining the global prevalence of clinically relevant levels of psychological distress and somatic symptoms and the prevalence of coexistence between these symptoms and Disorders of Gut-Brain Interaction (DGBI). We also analyzed how clinically relevant psychological distress and somatic symptoms and coexistent DGBI are associated with health-related outcomes. METHODS: We included a representative sample of 54,127 adult participants (49,1% women; mean age of 44...
September 18, 2023: American Journal of Gastroenterology
#7
REVIEW
Baha Moshiree, Douglas Drossman, Aasma Shaukat
DESCRIPTION: Belching, bloating, and abdominal distention are all highly prevalent gastrointestinal symptoms and account for some of the most common reasons for patient visits to outpatient gastroenterology practices. These symptoms are often debilitating, affecting patients' quality of life, and contributing to work absenteeism. Belching and bloating differ in their pathophysiology, diagnosis, and management, and there is limited evidence available for their various treatments. Therefore, the purpose of this American Gastroenterological Association (AGA) Clinical Practice Update is to provide best practice advice based on both controlled trials and observational data for clinicians covering clinical features, diagnostics, and management considerations that include dietary, gut-directed behavioral, and drug therapies...
September 2023: Gastroenterology
#8
JOURNAL ARTICLE
Ami D Sperber, Serhat Bor, Xuicai Fang, Shrikant I Bangdiwala, Douglas A Drossman, Uday C Ghoshal, Magnus Simren, Jan Tack, William E Whitehead, Dan L Dumitrascu, Shin Fukudo, John Kellow, Edith Okeke, Eamonn M M Quigley, Max Schmulson, Peter Whorwell, Timothy Archampong, Payman Adibi, Viola Andresen, Marc A Benninga, Bruno Bonaz, Luis Bustos Fernandez, Suck Chei Choi, Enrico S Corazziari, Carlos Francisconi, Albis Hani, Leonid Lazebnik, Yeong Yeh Lee, Agata Mulak, M Masudur Rahman, Javier Santos, Mashiko Setshedi, Ari Fahrial Syam, Stephen Vanner, Reuben K Wong, Aurelio Lopez-Colombo, Valeria Costa, Ram Dickman, Motoyori Kanazawa, Ammar Hassanzadeh Keshteli, Rutaba Khatun, Iradj Maleki, Pierre Poitras, Nitesh Pratap, Oksana Stefanyuk, Sandie Thomson, Murat Buyruk, Nalan Unal, Dan Huang, Jun Song, Johann P Hreinsson, Olafur S Palsson
BACKGROUND AND AIMS: The Rome Foundation Global Epidemiology Study (RFGES) assessed the prevalence, burden, and associated factors of Disorders of Gut-Brain Interaction (DGBI) in 33 countries around the world. Achieving worldwide sampling necessitated use of two different surveying methods: In-person household interviews (9 countries) and Internet surveys (26 countries). Two countries, China and Turkey, were surveyed with both methods. This paper examines the differences in the survey results with the two methods, as well as likely reasons for those differences...
April 5, 2023: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#9
JOURNAL ARTICLE
Jóhann P Hreinsson, Hans Törnblom, Jan Tack, Douglas A Drossman, William E Whitehead, Shrikant I Bangdiwala, Ami D Sperber, Olafur S Palsson, Magnus Simrén
BACKGROUND & AIMS: The Rome criteria are widely accepted for diagnosing disorders of gut-brain interaction, but their global applicability has been debated. This study aimed to evaluate the validity of the Rome IV criteria by factor analysis globally, across geographical regions, by sex, and by age groups. METHODS: Data were collected in 26 countries using the Rome IV questionnaire. Forty-nine ordinal variables were used in exploratory factor analysis (EFA) to identify clusters of inter-correlated variables (factors) within the data set...
June 2023: Gastroenterology
#10
JOURNAL ARTICLE
Brian E Lacy, Laurie Keefer, Douglas A Drossman
No abstract text is available yet for this article.
March 1, 2023: American Journal of Gastroenterology
#11
JOURNAL ARTICLE
Chloé Melchior, Katarina Wilpart, Irina Midenfjord, Inês A Trindade, Hans Törnblom, Jan F Tack, Magnus Simrén, Lukas Van Oudenhove
OBJECTIVE: This study aimed to investigate the associations between the different abuse types, and gastrointestinal (GI) and extraintestinal symptom severity in irritable bowel syndrome (IBS), and possible mediators of these relationships. METHODS: We assessed sexual and physical abuse in childhood and adulthood with the Drossman and Leserman abuse questionnaire, whereas GI and extraintestinal symptoms were assessed with the Gastrointestinal Symptom Rating Scale and the Symptom Check List-90 Revised...
November 2022: Psychosomatic Medicine
#12
JOURNAL ARTICLE
Xiu-Cai Fang, Wen-Juan Fan, Douglas D Drossman, Shao-Mei Han, Mei-Yun Ke
BACKGROUND: The Rome IV criteria eliminated abdominal discomfort for irritable bowel syndrome (IBS), which was previously included in Rome III. There are questions as to whether IBS patients with abdominal discomfort (seen in Rome III but not Rome IV) are different from those with abdominal pain (Rome IV). AIM: To compare bowel symptoms and psychosocial features in IBS patients diagnosed with Rome III criteria with abdominal discomfort, abdominal pain, and pain & discomfort...
September 7, 2022: World Journal of Gastroenterology: WJG
#13
JOURNAL ARTICLE
Yuanfang Chen, Baotao Lian, Peize Li, Simeng Yao, Zhengkun Hou
Irritable bowel syndrome (IBS) associated with anxiety or depression is ubiquitous in clinical practice, and multiple related articles have been published. However, studies that utilize bibliometric analyses to address this topic are rare. In our study, we aimed to reveal research trends in IBS with anxiety or depression. Publications on IBS in relation to anxiety or depression in the last 20 years were obtained from the Web of Science Core Collection (WoSCC). CiteSpace software (5.8.R3) and GraphPad Prism 8 were used to perform bibliometric analysis of authors, countries, institutions, journals, keywords, and references involved in this topic...
2022: Frontiers in Public Health
#14
EDITORIAL
Tack Jan, Douglas A Drossman
The Rome Foundation embarked on an ambitious multi-year, multinational population-based study to evaluate the prevalence of Rome IV-defined DGBI and their biopsychosocial impact on a worldwide scale. The consistency of the study findings attests to the scientific rigor of this effort, as evident in the publications that resulted from this international study. Dr. Sperber and colleagues report a subanalysis on the Rome IV Global Epidemiology internet survey of the 2012 adults in Israel. These data determined the national prevalence of Rome IV-defined DGBIs, and their associated healthcare utilization and sociodemographic and psychosocial variables...
August 2022: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#15
EDITORIAL
Miranda A L van Tilburg, Douglas A Drossman, Simon R Knowles
No abstract text is available yet for this article.
November 24, 2021: Journal of Psychosomatic Research
#16
REVIEW
Mihaela Fadgyas Stanculete, Dan Lucian Dumitrascu, Douglas Drossman
Irritable bowel syndrome (IBS) is a clinically well-defined chronic condition that is now understood as a disorder of gut-brain regulation, as established in the work of the Rome IV committees coordinated by Drossman, 2016. People with IBS often report high disability levels and poor health-related quality of life. Drug therapy focuses on reducing main symptoms and disability and improving health-related quality of life. Central neuromodulators reduce IBS symptoms by targeting dysregulated pain and motility related to gut-brain dysregulation...
November 23, 2021: Journal of Gastrointestinal and Liver Diseases: JGLD
#17
JOURNAL ARTICLE
Douglas A Drossman, Jan Tack
No abstract text is available yet for this article.
March 2022: Gastroenterology
#18
REVIEW
Laurie Keefer, Sarah K Ballou, Douglas A Drossman, Gisela Ringstrom, Sigrid Elsenbruch, Brjánn Ljótsson
BACKGROUND AND AIMS: This Rome Foundation Working Team Report reflects the consensus of an international interdisciplinary team of experts regarding the use of behavioral interventions, specifically brain-gut behavior therapies (BGBTs), in patients with disorders of gut-brain interaction (DGBIs). METHODS: The committee members reviewed the extant scientific literature and, when possible, addressed gaps in this literature through the lens of their clinical and scientific expertise...
January 2022: Gastroenterology
#19
REVIEW
Douglas A Drossman, Lin Chang, Jill K Deutsch, Alexander C Ford, Albena Halpert, Kurt Kroenke, Samuel Nurko, Johannah Ruddy, Julie Snyder, Ami Sperber
BACKGROUND & AIMS: Over several decades, changes in health care have negatively impacted meaningful communication between the patient and provider and adversely affected their relationship. Under increasing time pressure, physicians rely more on technology than face-to-face time gathering data to make clinical decisions. As a result, they find it more challenging to understand the illness context and fully address patient needs. Patients experience dissatisfaction and a diminution of their role in the care process...
November 2021: Gastroenterology
#20
REVIEW
Hans Törnblom, Douglas A Drossman
Psychopharmacologic therapies are beneficial in reducing symptoms when treating irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBI). Noradrenaline, serotonin, and dopamine are neurotransmitters of key importance in psychopharmacology and pain-reduction mechanisms. The first-line (tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors, selective serotonin reuptake inhibitors) and second-line (atypical antipsychotics, delta-ligand agents, low-dose naltrexone) neuromodulator treatment options are recommended when IBS-associated abdominal pain is of moderate or severe intensity and is persistent...
September 2021: Gastroenterology Clinics of North America
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
